AC Immune SA EBITDA margin
Quel est le EBITDA margin de AC Immune SA?
Le EBITDA margin de AC Immune SA est 293.05%
Quelle est la définition de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin des entreprises dans Health Care secteur sur NASDAQ par rapport à AC Immune SA
Que fait AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Entreprises avec ebitda margin similaire à AC Immune SA
- Western Asset Inflation-Linked Income Fund a EBITDA margin de 279.93%
- Banimmo SA a EBITDA margin de 282.01%
- Nuveen New Jersey Municipal Value Fund a EBITDA margin de 284.57%
- Wellness and Beauty Solutions a EBITDA margin de 287.70%
- BP Prudhoe Bay Royalty Trust a EBITDA margin de 288.86%
- First Trust Dynamic Europe Equity Income Fund a EBITDA margin de 289.58%
- AC Immune SA a EBITDA margin de 293.05%
- Norvista Capital a EBITDA margin de 294.05%
- abrdn Japan Equity Fund Inc a EBITDA margin de 294.71%
- Allied Hotel Properties a EBITDA margin de 298.57%
- Gabelli Healthcare & WellnessRx Trust a EBITDA margin de 301.04%
- Nuveen California AMT-Free Quality Municipal Income Fund a EBITDA margin de 301.50%
- Gabelli Global Small and Mid Cap Value Trust a EBITDA margin de 301.61%